SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?


To: D.Right who wrote (1003)12/10/1997 6:03:00 PM
From: David Bogdanoff  Read Replies (1) | Respond to of 2173
 
To all;

Its safe to say that the momentum players have cleared out of this stock, imo. Considering the safety problems of rezulin, it should be
clear to all to see how difficult a good diabietes drug is to develop.
This makes pramlintide look good. Yearend tax selling and weak biotech market have made this stock very cheap (not to say it won't get a bit cheaper).

David